VIP

Beskrivelse

VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide originally isolated from the small intestine, belonging to the secretin/glucagon family. It acts as a neurotransmitter, neuromodulator, and hormone with widespread receptors throughout the body (especially in the gastrointestinal tract, lungs, vascular smooth muscle, immune cells, and central nervous system). VIP exerts powerful anti-inflammatory, immunomodulatory, bronchodilatory, vasodilatory, and cytoprotective effects by binding to VPAC1 and VPAC2 receptors, activating adenylate cyclase, increasing intracellular cAMP, and modulating pathways like NF-κB, cytokine production, and T-cell differentiation. Clinically, VIP (or its analogs) has been studied and used off-label for conditions such as pulmonary hypertension, inflammatory bowel disease (Crohn’s and ulcerative colitis), sarcoidosis, autoimmune disorders, chronic inflammatory response syndrome (CIRS), mold illness, mast cell activation syndrome (MCAS), and certain neurodegenerative or neuroinflammatory conditions due to its ability to downregulate pro-inflammatory cytokines (TNF-α, IL-6, IL-12), promote regulatory T-cells, protect epithelial barriers, reduce intestinal permeability, and support tissue healing. In wellness, anti-aging, and integrative medicine circles, VIP is researched via nasal spray (most common route for direct CNS and systemic effects, typical doses 50–200 mcg per nostril 1–4 times daily) or subcutaneous injection for purported benefits including reduced systemic inflammation, improved gut-brain axis function, better tolerance to environmental triggers, enhanced mood and stress resilience, support for detoxification, and overall immune balance. Anecdotal reports often highlight rapid improvements in brain fog, fatigue, joint pain, digestive symptoms, and inflammatory markers in complex chronic illness cases. VIP is generally well-tolerated with common side effects limited to mild nasal irritation (spray form), transient flushing, headache, or loose stools; serious adverse events are rare but may include hypotension in sensitive individuals or interactions with blood pressure medications. However, VIP is not FDA-approved for broad therapeutic use in most indications as of 2026—approved formulations are extremely limited (e.g., historical use in certain pulmonary hypertension contexts), and current availability occurs primarily through compounding pharmacies for off-label or investigational applications. It requires prescription and close medical supervision with baseline and follow-up monitoring (inflammatory markers, blood pressure, electrolytes) due to its potent vasoactive and immunomodulatory properties. VIP should never be used without guidance from a qualified healthcare provider experienced in peptide therapy or complex inflammatory conditions, as self-administration carries risks of improper dosing, contamination from unregulated sources, adverse reactions, or exacerbation of certain underlying issues. Prioritize evidence-based treatments and comprehensive diagnostics for chronic inflammation or autoimmune concerns—consult a specialist to determine if VIP fits your individualized protocol.

ALSO SEE